SIGA Announces Lead Smallpox Drug is in Preclinical Development
NEW YORK -- SIGA Technologies, Inc. has announced that its smallpox drug, SIGA-246, has entered preclinical development. Based on an emerging understanding of the mechanism of action and protective efficacy in four different murine challenge models, SIGA-246 has progressed to preclinical lead status. SIGA has initiated IND-enabling scale-up synthesis, formulation, pharmacology, and toxicology studies on the drug in order to allow primate efficacy and human safety studies to be performed later this year.
"To date, all the data we've generated indicates that SIGA-246 is a very promising smallpox antiviral drug candidate. Therefore, with the advice and support of the National Institutes of Health (NIH), we are aggressively pursuing pre-clinical development of the drug to enable advancing it towards human clinical studies as soon as possible," said Dr. Dennis E. Hruby, chief scientific officer of SIGA.
Smallpox virus is considered one of the most significant threats for use as a bioterrorism agent due to the fact that since 1972 people in the United States have not been vaccinated against it. Smallpox is very easily transmitted from person to person, and has high mortality rates (30 percent to 60 percent) with 90 percent morbidity. It is classified as a Category A agent by the Centers for Disease Control and Prevention (CDC). Mass immunizations of the general population using the current live vaccine are not recommended, as there are known complications in certain individuals from vaccination (including encephalitis, myocarditis, disseminated vaccinia virus infection, and death). At present there is no treatment for smallpox that can be safely administered to the general population without significant risk of adverse reactions.
In addition to smallpox, SIGA also has antiviral programs targeting other Category A pathogens which cause hemorrhagic fevers, including the arenaviruses (Lassa Fever Virus, Junin, Macupo, Guanarito, and Sabia), Lymphocytic choriomeningitis virus (LCMV), Dengue, and the filoviruses, Ebola and Marburg.
SIGA's CEO, Bernard L. Kasten, MD, stated, "SIGA's continued success in the development of SIGA-246 as a safe and effective drug for the treatment of smallpox, along with SIGA's progress in advancing other critical BioShield drugs needed to provide national and international protection against Category A bioterrorist threats, positions SIGA as an emerging leader in the biodefense sector."
Source: SIGA Technologies, Inc.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
